Suppr超能文献

RPL15过表达在肝内胆管癌中的预后影响:侵袭性肿瘤行为的一个标志物

Prognostic impact of RPL15 overexpression in intrahepatic cholangiocarcinoma: a marker of aggressive tumor behavior.

作者信息

Wang Wen-Ching, Huang Chien-Jui, Hsu Han-Ping, Kuo Yu-Hsuan, Ong Khaa Hoo, Sun Ding-Ping, Tian Yu-Feng, Chou Chia-Ling, Chan Ti-Chun, Hsing Chung-Hsi, Li Wan-Shan, He Hong-Lin

机构信息

Division of Gastroenterology & General Surgery, Department of Surgery, Chi Mei Medical Center, Tainan, Taiwan.

Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.

出版信息

Diagn Pathol. 2025 Sep 1;20(1):101. doi: 10.1186/s13000-025-01699-y.

Abstract

BACKGROUND

Overexpression of ribosomal proteins has been found in several cancer types and has an important role in cell proliferation and tumorigenesis. Analysis of the expression profiles of cholangiocarcinoma revealed that ribosomal protein L15 (RPL15) was significantly upregulated in cancer tissues compared to surrounding liver and biliary tissues. Thus, we tried to investigate the role of RPL15 in intrahepatic cholangiocarcinoma.

METHODS

The expression of RPL15 in intrahepatic cholangiocarcinoma was assessed using immunohistochemistry. The relationships between RPL15 expression levels and clinicopathological parameters were analyzed, along with investigating its prognostic significance in overall survival (OS), disease-specific survival (DSS), local recurrence-free survival (LRFS) and metastasis-free survival (MeFS).

RESULTS

In the cohort comprising 182 patients with intrahepatic cholangiocarcinoma, high expression of RPL15 was significantly associated with advanced tumor (pT) stage (P = 0.005) and high histological grade (P = 0.018). In univariate analyses, overexpression of RPL15 predicted worse DSS (P = 0.0001), LRFS (P < 0.0001) and MeFS (P < 0.0001), but not OS (P = 0.3960). Multivariate analyses revealed that RPL15 overexpression independently predicted worse DSS (P = 0.039), LRFS (P < 0.001) and MeFS (P < 0.001).

CONCLUSIONS

Overexpression of RPL15 was identified as an adverse prognostic factor predicting worse outcomes in intrahepatic cholangiocarcinoma. RPL15 could serve as a potential therapeutic target to aid in developing new treatment strategies.

摘要

背景

核糖体蛋白的过表达已在多种癌症类型中被发现,并且在细胞增殖和肿瘤发生中起重要作用。胆管癌表达谱分析显示,与周围肝组织和胆管组织相比,核糖体蛋白L15(RPL15)在癌组织中显著上调。因此,我们试图研究RPL15在肝内胆管癌中的作用。

方法

采用免疫组织化学方法评估RPL15在肝内胆管癌中的表达。分析RPL15表达水平与临床病理参数之间的关系,并研究其在总生存期(OS)、疾病特异性生存期(DSS)、无局部复发生存期(LRFS)和无转移生存期(MeFS)中的预后意义。

结果

在包括182例肝内胆管癌患者的队列中,RPL15的高表达与肿瘤(pT)晚期(P = 0.005)和高组织学分级(P = 0.018)显著相关。在单因素分析中,RPL15的过表达预示着更差的DSS(P = 0.0001)、LRFS(P < 0.0001)和MeFS(P < 0.0001),但与OS无关(P = 0.3960)。多因素分析显示,RPL15过表达独立预示着更差的DSS(P = 0.039)、LRFS(P < 0.001)和MeFS(P < 0.001)。

结论

RPL15过表达被确定为预测肝内胆管癌预后较差的不良预后因素。RPL15可作为潜在的治疗靶点,有助于开发新的治疗策略。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验